About Us

KUSTE BIOPHARMA expands the use of these molecules to inflammatory urological diseases whose medical needs are currently unmet, such as Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
Preclinical data also supports other possible developments, for example on Inflammatory Bowel Disease (IBD).

KUSTE BIOPHARMA has closed a relevant financial round to launch Phase 2 clinical studies on BPS/IC and preclinical studies on other applications.